MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

(2009) T. E. Fandy et al.   BLOOD

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

An analytical pipeline for genomic representations used for cytosine methylation studies

(2008) Reid F. Thompson et al.   BIOINFORMATICS

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

(2008) Y. Jiang et al.   BLOOD

Azacytidine causes complex DNA methylation responses in myeloid leukemia

(2008) C. Stresemann et al.   MOLECULAR CANCER THERAPEUTICS

An Integrative Genomic and Epigenomic Approach for the Study of Transcriptional Regulation

(2008) Maria E. Figueroa et al.   PLoS One

DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes

(2008) Elizabeth A. Griffiths et al.   SEMINARS IN HEMATOLOGY